Currently, there are 38.27M common shares owned by the public and among those 35.88M shares have been available to trade.
The company’s stock has a 5-day price change of -2.13% and 55.61% over the past three months. ITOS shares are trading -40.45% year to date (YTD), with the 12-month market performance up to 31.90% higher. It has a 12-month low price of $4.80 and touched a high of $18.13 over the same period. ITOS has an average intraday trading volume of 1.40 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.21%, 6.32%, and 24.09% respectively.
Institutional ownership of ITeos Therapeutics Inc (NASDAQ: ITOS) shares accounts for 116.28% of the company’s 38.27M shares outstanding.
It has a market capitalization of $387.71M and a beta (3y monthly) value of 1.49. The earnings-per-share (ttm) stands at -$3.23. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.57% over the week and 1.42% over the month.
Earnings per share for the fiscal year are expected to increase by 3.92%, and 49.28% over the next financial year. EPS should grow at an annualized rate of 3.89% over the next five years, compared to -34.39% over the past 5-year period.
Looking at the support for the ITOS, a number of firms have released research notes about the stock. Wells Fargo stated their Equal Weight rating for the stock in a research note on May 28, 2025, with the firm’s price target at $12. Wedbush coverage for the ITeos Therapeutics Inc (ITOS) stock in a research note released on May 28, 2025 offered a Neutral rating with a price target of $12. JP Morgan on their part issued Neutral rating on May 13, 2025.
